Related Experiment Video
Updated: Feb 18, 2026

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
In vitro hepatic clearance of enniatin B1: interspecies and cell model comparison
M Mahdjoub1, E Dubreil2, C Gendre2
1Fougères Laboratory, ANSES French Agency for Food, Environmental and Occupational Health and Safety, Fougères - Rennes, France. mariam.mahdjoub@anses.fr.
Abstract:
Enniatin B1 (EnnB1) is a Fusarium-produced mycotoxin contaminating cereals and cereal-based products, which represent the main source of human exposure to the toxin. EnnB1 belongs to the "emerging mycotoxins" group that are not regulated due to data gaps on their toxicokinetic and toxicodynamic profiles. The aim of this study was to determine the in vitro hepatic clearance of EnnB1 based on parent compound depletion. To do this, we used two in vitro experimental assays-a conventional and a media loss assay-and compared hepatic clearance between (i) species, using primary rat and human hepatocytes, (ii) cell types, namely primary human hepatocytes and the HepaRG human hepatic cell line, and (iii) cell models by comparing 2D and 3D HepaRG. Hepatic clearance (ClH) was calculated from in vitro hepatic intrinsic clearance using in vitro to in vivo extrapolation. We found that the derived ClH was faster in rats compared to humans, i.e., 3.4 L/(h·kg) and 1 L/(h·kg), respectively. ClH was comparable between primary human hepatocytes and HepaRG 2D, while HepaRG 3D showed slower ClH of 0.58 L/(h·kg). We found that the media loss depletion assay revealed an initial phase of rapid uptake, then a slope parallel to that of the conventional depletion assay. We observed that the conventional depletion assay was appropriate to determine the ClH of EnnB1. Furthermore, the pooled primary hepatocytes, considering inter-individual variability, allowed the determination of a reliable ClH to be used in the development of a physiologically based pharmacokinetic model.
More Related Videos
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
07:23Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
Related Concept Videos
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...